Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Portfolio Pulse from Vandana Singh
Public Citizen, a consumer advocacy group, has petitioned the FDA to enforce stronger warnings on botulinum toxin injections like AbbVie's Botox, Revance Therapeutics' Daxxify, Evolus' Jeuveau, and Supernus Pharmaceuticals' Myobloc. The group cites over 5,400 adverse event reports and calls for clear labeling of the risk of systemic iatrogenic botulism, which can cause muscle paralysis. The FDA is set to review the petition.
December 12, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's Botox is targeted by Public Citizen for stronger FDA warnings due to paralysis risks.
The petition for stronger warnings could lead to heightened concerns among consumers and possibly affect Botox sales, negatively impacting AbbVie's stock in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Evolus' Jeuveau is among the products that may require stronger FDA warnings about botulism risks.
The push for more stringent warnings could potentially deter customers and negatively affect Jeuveau's market share, posing a risk to Evolus' stock in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Revance Therapeutics' Daxxify faces calls for increased FDA warnings about potential paralysis risks.
The advocacy for more explicit warnings may lead to consumer apprehension, potentially impacting the demand for Daxxify and Revance Therapeutics' stock price negatively in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Supernus Pharmaceuticals' Myobloc is under scrutiny for stronger warning labels due to botulism risks.
The petition for more comprehensive warnings on Myobloc could lead to a decrease in consumer confidence and potentially harm Supernus Pharmaceuticals' stock performance in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80